Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

Name: Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
Published: 2023
License: Public Domain

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

recurrent, or metastatic cervical cancer with pd-l1 positive (cps≥1), interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

Related documents